Is the continued use of UK plasma sourced cryoprecipitate justified? Response to Makris

Acquired hypofibrinogenemia: current perspectives

“…The cost advantage, however, is lost in patients born after January 1, 1996, as the national recommendation is to use methylene blue-treated non-UK-plasma products. 36 Particularly, before these patients constitute the majority of blood recipients, it is a major challenge to keep sufficient stock of MB-treated cryoprecipitate of the optimal blood group without causing wastage due to expiry, and there is a stringent requirement to infuse this within 4 hours of thawing. MF plasma products are approximately 5× as expensive as UK-based plasma products.…”